addICTed

[Herman Trading @RHerman]

Time to recap another week of GEM 8–9am.

Last week I showed this as a “GEM” inside the New York session.

This week I went back and did a quick Monday–Friday backtest to see if the 8–9am range still delivered.

And once again, the logic is simple:

Define the 8–9AM New York range.
Let the market show the more probable side.
Then trade only in that direction.
No guessing.
No forcing trades.
No flipping bias every 5 minutes.
Just probability first.
Confirmation second.
Execution third.

The whole point of GEM is not to predict every tick.

The point is to understand which side has the better odds before the main New York move develops.

Some days are clean.
Some days are choppy.
Some days give no valid entry.

But the model keeps you focused on one thing most traders ignore:
Direction before execution.
I’ll keep tracking this every week because this is exactly how real edge is built.

Not from one perfect trade.

From repeated behaviour, repeated sessions and repeated data.

GEM 8–9AM weekly recap below 👇

Would you trade the New York session differently if you already knew the more probable side is?

[Lozzy B 🇦🇺𝕏 @TruthFairy131]

David Irving was banned from
Australia in 1993 because he exposed the truth about WW2.

Foreign lobbies have been in control of Australian policy & our government for a long time now.

[Triton @TritonTrades]

this 30-minute candle can predict the correct bias 80% of the time

mark out the 9:30 to 10:00 am candle:

if it's bullish > there's a 82% chance NY is bullish
if it's bearish > there's a 74% chance NY is bearish

this is proven in the last 6 months of market data from Edgeful

[ICTstudent-Telugu @DisciplineICT_K]

MMXM in MNQ1!

[TTrades🦍 @TTrades_edu]

Breaking Down How to Use C3 Closures to Anticipate the Next Candle

[Drevax @Drevaxtrades]

MASTERING ICT "Dealing Ranges"

Understanding Algorithmic Price Delivery:

A Thread🧵

[F X 4 L I V I N G @fx4_living]

Nobody outside the circle has any idea how much deep sacrifice it takes to achieve success in trading.

As I said the other day, time will always remain the main investment.

That being said, time is something very valuable and precious of some sort; you technically can't sacrifice it all, but without the actual knowledge and the experience sitting behind the charts, these exceptional results are totally impossible.

So, in other words, you need to sacrifice some "fun" time to study these aka boring stuff that will over time pay for all of it.

[Herman Trading @RHerman]

Most traders are completely wrong about NQ NDOG.

They think:
“Gaps always fill.”

The data says something very different.

After analysing 2,791 NQ futures RTH sessions from Jan 2015 to Dec 2025, the full gap filled by close only 60.3% of the time.

But that number is almost useless without context.

Because the real edge is not “gap fill or no gap fill.”

The real edge is:

How big is the gap?
Where did it open?
Did the first 15-min candle confirm the fill?
A tiny NQ gap filled by close 77.8% of the time.
A large NQ gap filled only 8.2% of the time.

That is not a small difference.

That is the difference between fading a high-probability mean reversion setup…

And shorting directly into a potential trend day.

Even more interesting:

• 43.3% of full gap fills happen within the first hour
• 51.9% happen by noon
• The afternoon only adds 8.4 percentage points
• If the gap hasn’t filled by noon, you are often no longer trading probability
• You are trading hope

And here is the part most traders never measure:

When a tiny gap has early confirmation toward the fill, the probability can reach 89–93%.
That changes the whole way you look at the open.
NQ gaps are not random.
They are contextual.

Tiny gap + inside previous range + early move toward fill = mean reversion environment.

Large gap + outside previous range + high volatility = do not blindly fade it.

The market gives clues before most traders even realise the day has a structure.

This is why I don’t trade “opinions.”
I trade probabilities.

Would you rather fade every NQ gap blindly…
Or wait for the gap profile that actually has the odds behind it?

[Adi @TradebyAdi]

$NQ 9:30 gave the manipulation first.

Waited for the OB / FVG long and let NQ push back up.

[Lozzy B 🇦🇺𝕏 @TruthFairy131]

You were NEVER meant to fit in.

You have ALWAYS known that.

You THINK for yourself, you ASK big questions & you DON’T blindly follow the crowd.

You SPEAK out, STAND up & FIGHT for what you believe in.

You possess OLD wisdom & NEW insight.

You were NEVER meant to be ORDINARY 🤍

[Wide Awake Media @wideawake_media]

Scientist and author Gregg Braden: "Climate change is a fact... It's also a fact that humans are not causing it."

"Is there more CO₂ in the atmosphere now than there was 10 years, 20, 50, 100 years ago? The answer is absolutely yes."

"Is it a bad thing? The answer is no."

Credit: @GreggBraden @missmayim

[DayTradingRauf (DTR) @daytradingrauf]

Complete mechanical thread

Covering my time based ranges setups from the week of April 6th

🧵

[Josef @joseftrades]

Don’t tell anyone. Show them.

[Wide Awake Media @wideawake_media]

What if today's mental health crisis exists because we followed the wrong guy?

[GorillaScience @WatchGorillaSci]

Time for some ACCURATE Climate Data!
@Martin_Durkin @TomANelson @CO2Coalition @HeartlandInst

[Nicolas Hulscher, MPH @NicHulscher]

🚨BREAKING: Largest Real-World Study of Ivermectin + Mebendazole in Cancer Patients Shows 84.4% Clinical Benefit — Nearly HALF Report Cancer Disappearance or Tumor Regression

After just 6 months, 48.4% of cancer patients taking ivermectin and mebendazole reported NO EVIDENCE OF DISEASE (32.8%) or tumor regression (15.6%), while 36.1% reported disease stabilization⬇️

We have completed the largest real-world human analysis to date evaluating ivermectin and mebendazole in cancer patients—and the results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.

The groundbreaking analysis was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel (Dr. Harvey Risch)—uniting real-world clinical data, frontline medical experience, and high-level epidemiologic expertise to deliver urgently needed insights in oncology.

This was a real-world prospective clinical program evaluation of 197 cancer patients, with 122 completing a follow-up survey at about six months (61.9% response rate).

Cancer patients were prescribed compounded ivermectin–mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole—most commonly taken at 1–2 capsules per day.

The cohort represented a clinically relevant population, including a wide variety cancer types, with 37.1% of patients reporting actively progressing disease at baseline and many having already undergone chemotherapy, radiation, and surgery.

At six months, 84.4% of cancer patients reported clinical benefit (Clinical Benefit Ratio: 84.4% [95% CI: 77.0–89.8%]):

✅ 32.8% reported no evidence of disease (95% CI: 25.1–41.5%)
✅ 15.6% reported tumor regression (95% CI: 10.2–23.0%)
✅ 36.1% reported stable disease (95% CI: 28.1–44.9%)

Treatment adherence was high, with 86.9% completing the full protocol and 66.4% remaining on therapy at six months.

The regimen was well tolerated, with 25.4% reporting side effects, primarily mild and gastrointestinal, and over 93% continuing treatment despite these events.

Patients were treated in real-world conditions alongside concurrent therapies, including chemotherapy (27.9%), radiation (21.3%), surgery (19.7%), supplements (49.2%), and dietary modification (37.7%), supporting use as an adjunctive approach.

Together, these findings represent a large, internally consistent real-world clinical signal that supports URGENT further investigation of ivermectin and mebendazole as low-toxicity, adjunctive cancer therapies.

Given the strength of the signal observed here, advancing this line of investigation is no longer optional—it is necessary.

This is NOT the end. We will continue advancing this work with larger datasets to further define and validate the role of anti-parasitics in cancer outcomes.

The manuscript is now available as a preprint on the Zenodo research repository, operated by the European Organization for Nuclear Research, while undergoing peer review at leading oncology journals: “Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.”

@twc_health @McCulloughFund @P_McCulloughMD @DrHarveyRisch @DrKellyVictory @jathorpmfm @drdrew @PeterGillooly @FosterCoulson

[“Sudden And Unexpected” @toobaffled]

Many of those people who cursed at us for NOT getting the jab have now left this world to prove us right.

[Malcolm Roberts 🇦🇺 @MRobertsQLD]

To date, more than $1 billion in taxpayer funds has been spent on this failing program. We must ask: at what stage do we say - "enough is enough"?

This program requires an urgent review and a reconsideration of how fire ants are managed. We cannot continue to use taxpayer money on a strategy that is proving both ineffective and harmful.

Thanks Sarah, for your commitment and for giving the community a voice in this cause.

Original video taken from @ Fire Ant Treatment Alternatives on Instagram.

[Tanja Trades @TanjaTrades]

AI is the future, adapt or get left behind
this is crazy cool

[𝙲𝚘𝚗𝚜𝚎𝚛𝚟𝚊𝚝𝚒𝚟𝚎 👑 𝙳𝚒𝚟𝚊™ @1776Diva]

She was once a Muslim, now a Christian convert.

Listen as she takes one of the favorite arguments used by Muslims to trip up Christians, and completely dismantles it with God's Word.

Do you know Scripture well enough to combat the lies?